Difficult asthma

Asthma is usually easy to manage, but approximately 5% of patients are not controlled even on high doses of inhaled corticosteroids. It is important to assess these patients carefully in order to identify whether there are any correctable factors that may contribute to their poor control. It is critical to make a diagnosis of asthma and to exclude other airway diseases, particularly chronic obstructive pulmonary disease (COPD), and vocal cord dysfunction ("pseudo-asthma"). Poor adherence to therapy, particularly inhaled corticosteroids, is a common reason for a poor response. There may be unidentified exacerbating factors, including unrecognized allergens, occupational sensitizers, dietary additives, drugs, gastro-oesophageal reflux, upper airway disease, or other systemic diseases, that need to be identified and avoided or treated. Psychological factors may be important in some patients, but it is difficult to know whether these are causal or secondary to troublesome disease. Some patients have instability of their asthma, with resistant nocturnal asthma, premenstrual exacerbations or chaotic and unpredictable instability (brittle asthma). A few patients are completely resistant to corticosteroids, but more patients are relatively resistant and require relatively high doses of corticosteroids to control their symptoms (steroid-dependent). Some patients develop progressive loss of lung function, as in patients with COPD. Management of patients with difficult asthma should be supervised by a respiratory specialist and should involve careful assessment to confirm a diagnosis of asthma, identification and treatment of exacerbating factors, particularly allergens, and recording of peak expiratory flow patterns. A period of hospital admission may be the best way to assess and manage these patients. Treatment involves optimizing corticosteroids therapy, assessing additional controllers such as long-acting inhaled or subcutaneous beta2-agonists or subcutaneous, theophylline and antileukotrienes. In some patients, the use of immunosuppressive treatments may reduce steroid requirements, although these treatments are rarely effective and have side-effects. In the future, the nonsteroid anti-inflammatory treatments now in development may be useful in these patients.

This article has been cited by other articles:

				J. Gamble, M. Stevenson, E. McClean, and L. G. Heaney The Prevalence of Nonadherence in Difficult Asthma Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 817 - 822. [Abstract] [Full Text] [PDF]

				M. E. Wechsler Managing Asthma in Primary Care: Putting New Guideline Recommendations Into Context Mayo Clin. Proc., August 1, 2009; 84(8): 707 - 717. [Abstract] [Full Text] [PDF]

				G. P Currie, J G. Douglas, and L. G Heaney Difficult to treat asthma in adults BMJ, February 24, 2009; 338(feb24_1): b494 - b494. [Full Text]

				J. Shannon, P. Ernst, Y. Yamauchi, R. Olivenstein, C. Lemiere, S. Foley, L. Cicora, M. Ludwig, Q. Hamid, and J. G. Martin Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma* Chest, February 1, 2008; 133(2): 420 - 426. [Abstract] [Full Text] [PDF]

				D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]

				J. A. Nathan, L. Pearce, C. Field, N. Dotesio-Eyres, L. D. Sharples, F. Cafferty, and C. M. Laroche A Randomized Controlled Trial of Follow-up of Patients Discharged From the Hospital Following Acute Asthma: Best Performed by Specialist Nurse or Doctor? Chest, July 1, 2006; 130(1): 51 - 57. [Abstract] [Full Text] [PDF]

				T. O. Kiljander, S. M. Harding, S. K. Field, M. R. Stein, H. S. Nelson, J. Ekelund, M. Illueca, O. Beckman, and M. B. Sostek Effects of Esomeprazole 40 mg Twice Daily on Asthma: A Randomized Placebo-controlled Trial Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1091 - 1097. [Abstract] [Full Text] [PDF]

				D. W. Denning, B. R. O'Driscoll, C. M. Hogaboam, P. Bowyer, and R. M. Niven The link between fungi and severe asthma: a summary of the evidence. Eur. Respir. J., March 1, 2006; 27(3): 615 - 626. [Abstract] [Full Text] [PDF]

				M. E. Strek Difficult asthma. Proceedings of the ATS, January 1, 2006; 3(1): 116 - 123. [Abstract] [Full Text] [PDF]

				Poster presentations Thorax, December 1, 2005; 60(suppl_2): ii53 - ii120. [Full Text] [PDF]

				A. ten Brinke, P. J. Sterk, A. A. M. Masclee, P. Spinhoven, J. T. Schmidt, A. H. Zwinderman, K. F. Rabe, and E. H. Bel Risk factors of frequent exacerbations in difficult-to-treat asthma Eur. Respir. J., November 1, 2005; 26(5): 812 - 818. [Abstract] [Full Text] [PDF]

				L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Eur. Respir. J., January 1, 2005; 25(1): 41 - 46. [Abstract] [Full Text] [PDF]

				P. J. Barnes Corticosteroid Resistance in Airway Disease Proceedings of the ATS, November 1, 2004; 1(3): 264 - 268. [Abstract] [Full Text] [PDF]

				S. B. Haga and W. Burke Using Pharmacogenetics to Improve Drug Safety and Efficacy JAMA, June 16, 2004; 291(23): 2869 - 2871. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]

				The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur. Respir. J., September 1, 2003; 22(3): 470 - 477. [Abstract] [Full Text] [PDF]

				D.S. Robinson, D.A. Campbell, S.R. Durham, J. Pfeffer, P.J. Barnes, and K.F. Chung Systematic assessment of difficult-to-treat asthma Eur. Respir. J., September 1, 2003; 22(3): 478 - 483. [Abstract] [Full Text] [PDF]

				L G Heaney, E Conway, C Kelly, B T Johnston, C English, M Stevenson, and J Gamble Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol Thorax, July 1, 2003; 58(7): 561 - 566. [Abstract] [Full Text] [PDF]

				D Soussan, R Liard, M Zureik, D Touron, Y Rogeaux, and F Neukirch Treatment compliance, passive smoking, and asthma control: a three year cohort study Arch. Dis. Child., March 1, 2003; 88(3): 229 - 233. [Abstract] [Full Text] [PDF]

				A. ten BRINKE, A. H. ZWINDERMAN, P. J. STERK, K. F. RABE, and E. H. BEL Factors Associated with Persistent Airflow Limitation in Severe Asthma Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 744 - 748. [Abstract] [Full Text] [PDF]

				M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, and G. Della Cioppa The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur. Respir. J., August 1, 2001; 18(2): 254 - 261. [Abstract] [Full Text] [PDF]

				J L Coughlan, P G Gibson, and R L Henry Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review Thorax, March 1, 2001; 56(3): 198 - 204. [Abstract] [Full Text]

				P. J. Barnes Anti-IgE Antibody Therapy for Asthma N. Engl. J. Med., December 23, 1999; 341(26): 2006 - 2008. [Full Text]